Identification of a major radiometabolite of [11C]PBB3.
暂无分享,去创建一个
Ming-Rong Zhang | M. Higuchi | Tomoteru Yamasaki | Joji Yui | K. Kawamura | Yasuyuki Kimura | Kenji Furutsuka | M. Takei | Masatoshi Muto | Takehito Ito | Hiroki Hashimoto | Tomoya Fujishiro | K. Nemoto | Nobuyuki Igarashi | Satoshi Shiomi | Ryuji Watanabe | Ming-Rong Zhang
[1] Ming-Rong Zhang,et al. PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.
[2] H. Arai,et al. [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Lin Xie,et al. Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.
[4] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[5] H. Wood. Alzheimer disease: [11C]PBB3—a new PET ligand that identifies tau pathology in the brains of patients with AD , 2013, Nature Reviews Neurology.
[6] J. Trojanowski,et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.
[7] H. Arai,et al. Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.
[8] Annelaure Damont,et al. Metabolism and Quantification of [18F]DPA-714, a New TSPO Positron Emission Tomography Radioligand , 2013, Drug Metabolism and Disposition.
[9] F. Dollé,et al. Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling: part II: Metabolism studies. , 2012, Nuclear medicine and biology.
[10] F. Dollé,et al. Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling Part I: PET studies. , 2012, Nuclear medicine and biology.
[11] Victor W Pike,et al. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. , 2009, Trends in pharmacological sciences.
[12] J. Trojanowski,et al. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.
[13] A. Kong,et al. Induction of phase I, II and III drug metabolism/transport by xenobiotics , 2005, Archives of pharmacal research.
[14] Jos H Beijnen,et al. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. , 2003, Toxicology and applied pharmacology.
[15] M. Takei,et al. Sensitive measurement of positron emitters eluted from HPLC. , 2001, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[16] S. Tannenbaum,et al. Sulfotransferase-mediated activation of 4-hydroxy- and 3,4-dihydroxy-3,4-dihydrocyclopenta[c,d]pyrene, major metabolites of cyclopenta[c,d]pyrene. , 1993, Cancer research.
[17] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.
[18] K. Tetsuka,et al. Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. , 2012, Drug metabolism and pharmacokinetics.